Phamaniaga submits regularisation plan to Bursa


PETALING JAYA: Pharmaniaga Bhd has submitted its regularisation plan to Bursa Malaysia, marking a critical milestone in its efforts to recover, enhance its financial standing and exit Practice Note 17 (PN17) status.

The pharmaceutical group, in a statement, said the regularisation plan outlines a holistic approach to increase the equity of the group and minimise the group’s accumulated losses.

“The rights issue offers the existing shareholders the opportunity to increase their participation in the future upside of Pharmaniaga, alongside a private placement aimed at drawing potential strategic investors to contribute to the group’s value enhancement and growth in the healthcare sector,” it said.

The Group's major shareholders, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd (BHB) have committed to ensure their combined entitlement to the rights issue, totalling RM190mil to be fully taken up.

“Pending approval from Bursa Malaysia, the plan is projected to be fully implemented in the fourth quarter of the fiscal year ending Dec 31, 2024,” Pharmaniaga said.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Pharmaniaga , Regularisation Plan , PN17

   

Next In Business News

DNB denies claims of impropriety over 5G rollout
Oil gains as Iran downplays reported Israeli attack
Maxis pledges full support to government’s 5G delivery model
Fajarbaru Builder secures RM13mil job
MKH Oil Palm IPO oversubscribed
Making the Malaysian startup pitch
The pros and cons of earned wage access
Making every load lighter
Batik, chips and tech in the fabric of society
How Sin-Kung leveraged air cargo for its success

Others Also Read